• Regulatory NewsRegulatory News

    Senators Look to Halt Price Spikes of Off-Patent Drugs

    Sens. Susan Collins (R-ME) and Claire McCaskill (D-MO) on Wednesday released a 131-page report explaining the details behind specific price increases for off-patent drugs and ways Congress can combat such spikes. The report offers a long look at the Senate Special Committee on Aging’s investigation from 2016 into the price increases of a number of targeted and acquired drugs from four companies including, Turing Pharmaceuticals , Valeant Pharmaceuticals , Retrophin I...
  • Regulatory NewsRegulatory News

    Senators Slam Execs of Shkreli's Former Company Over Arbitrary Price Hike on Lifesaving Drug

    The Senate’s Special Committee on Aging held its second hearing on pharmaceutical pricing on Thursday, this time taking shots at executives of Martin Shkreli’s former company Turing Pharmaceuticals, which only exists because of a monopoly and 5,000% price hike on a toxoplasmosis drug first approved more than 50 years ago. The first panel of witnesses included a couple whose newborn was diagnosed with toxoplasmosis but after their insurers denied coverage for the drug, kn...
  • Regulatory NewsRegulatory News

    Pediatric Priority Review Voucher Program Set to End After FDA Approves New Drug

    The US Food and Drug Administration's (FDA) rare pediatric disease priority review voucher program is slated to end in one year, after the agency awarded its third-ever rare pediatric voucher, thereby triggering a little-known provision in the voucher program. Background Regular readers of Regulatory Focus will be familiar with FDA's priority review voucher programs. We've written about them extensively over the years, and the vouchers are the focus of our most rec...